DK0637238T3 - Behandling af makuløs degenerering - Google Patents

Behandling af makuløs degenerering

Info

Publication number
DK0637238T3
DK0637238T3 DK93909617T DK93909617T DK0637238T3 DK 0637238 T3 DK0637238 T3 DK 0637238T3 DK 93909617 T DK93909617 T DK 93909617T DK 93909617 T DK93909617 T DK 93909617T DK 0637238 T3 DK0637238 T3 DK 0637238T3
Authority
DK
Denmark
Prior art keywords
macular degeneration
treatment
disease
deprenyl
ameliorate
Prior art date
Application number
DK93909617T
Other languages
English (en)
Inventor
Hastings Barbara A Fries
Original Assignee
Somerset Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somerset Pharmaceuticals Inc filed Critical Somerset Pharmaceuticals Inc
Application granted granted Critical
Publication of DK0637238T3 publication Critical patent/DK0637238T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Semiconductor Lasers (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK93909617T 1992-04-23 1993-04-23 Behandling af makuløs degenerering DK0637238T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/872,839 US5242950A (en) 1992-04-23 1992-04-23 Treatment of macular degeneration
PCT/US1993/003862 WO1993021894A2 (en) 1992-04-23 1993-04-23 Treatment of macular degeneration

Publications (1)

Publication Number Publication Date
DK0637238T3 true DK0637238T3 (da) 1999-08-30

Family

ID=25360402

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93909617T DK0637238T3 (da) 1992-04-23 1993-04-23 Behandling af makuløs degenerering

Country Status (14)

Country Link
US (1) US5242950A (da)
EP (1) EP0637238B1 (da)
JP (1) JP2669721B2 (da)
AT (1) ATE175348T1 (da)
AU (1) AU679679B2 (da)
BR (1) BR9306283A (da)
CA (1) CA2133998C (da)
DE (1) DE69322957T2 (da)
DK (1) DK0637238T3 (da)
ES (1) ES2127819T3 (da)
GR (1) GR3029670T3 (da)
HU (1) HU224917B1 (da)
NO (1) NO944018D0 (da)
WO (1) WO1993021894A2 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025380A (en) * 1990-12-14 2000-02-15 Smithkline Beecham Plc Medicament
US5783606A (en) * 1995-02-10 1998-07-21 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
US5462746A (en) * 1992-11-02 1995-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation
US6348208B1 (en) 1995-01-13 2002-02-19 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6299901B1 (en) 1995-01-13 2001-10-09 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
US6319954B1 (en) 1995-01-13 2001-11-20 Somerset Pharmaceuticals, Inc. S-(+)-desmethylselegiline and its use in the therapeutic methods and pharmaceutical compositions
EP0808160A1 (en) 1995-02-10 1997-11-26 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
IL122484A0 (en) * 1995-06-07 1998-06-15 Noven Pharma Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
US5827652A (en) 1995-10-31 1998-10-27 Applied Food Biotechnology, Inc. Zeaxanthin formulations for human ingestion
DK0866691T4 (da) * 1995-11-06 2005-06-06 Somerset Pharmaceuticals Inc Medikamenter til sublingual og bukkal administration af selegilin
CA2322878C (en) 1998-03-16 2008-05-06 Somerset Pharmaceuticals, Inc. Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
US7691406B2 (en) * 2000-10-27 2010-04-06 ZeaVision LLC. Zeaxanthin formulations for human ingestion
EP1441708B1 (en) * 2001-11-05 2009-04-08 Krele Pharmaceuticals LLC Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
US8088363B2 (en) * 2002-10-28 2012-01-03 Zeavision Llc Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin
EP1565185A4 (en) * 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
US9192586B2 (en) 2003-03-10 2015-11-24 Zeavision Llc Zeaxanthin formulations with additional ocular-active nutrients, for protecting eye health and treating eye disorders
US20040180090A1 (en) * 2003-03-12 2004-09-16 Demarco Peter Treatment of macular degeneration
US20050009862A1 (en) * 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
US20070082066A1 (en) * 2003-05-07 2007-04-12 Gierhart Dennis L Use of zeaxanthin to reduce light hyper-sensitivity, photophobia, and medical conditions relating to light hyper-sensitivity
US7941211B2 (en) * 2003-11-17 2011-05-10 Zeavision, Llc. Preloading with macular pigment to improve photodynamic treatment of retinal vascular disorders
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
EP1686973A4 (en) * 2003-11-25 2009-03-25 Technion Res & Dev Foundation COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISEASES
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
US20090208556A1 (en) 2004-10-29 2009-08-20 Regents Of The University Of California, The Porous photonic crystals for drug delivery to the eye
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
CN101495185A (zh) * 2006-07-28 2009-07-29 爱尔康研究有限公司 用于治疗外层视网膜病症的单胺氧化酶抑制剂
CA2905205A1 (en) 2007-07-10 2009-01-15 The Regents Of The University Of California A drug delivery device comprising a porous sio2 film or a sio2/polymer film
PL2531181T3 (pl) 2010-02-03 2019-09-30 Pharma Two B Ltd. Preparaty rasagiliny o przedłużonym uwalnianiu i ich zastosowanie
US9394369B2 (en) 2011-01-03 2016-07-19 The Regents Of The University Of California Luminescent porous silicon nanoparticles for targeted delivery and immunization
JP6894423B2 (ja) 2015-07-09 2021-06-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ 融合性リポソーム被覆多孔質ケイ素ナノ粒子

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197510B (en) * 1986-12-19 1989-04-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing phenyl-alkyl-amine derivatives, against motion-sick
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
US4868218A (en) * 1987-08-18 1989-09-19 Buyske Donald A Method of treating depression
GB8807504D0 (en) * 1988-03-29 1988-05-05 Sandoz Ltd Improvements in/relating to organic compounds
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same

Also Published As

Publication number Publication date
GR3029670T3 (en) 1999-06-30
DE69322957D1 (de) 1999-02-18
EP0637238B1 (en) 1999-01-07
AU679679B2 (en) 1997-07-10
EP0637238A1 (en) 1995-02-08
ATE175348T1 (de) 1999-01-15
DE69322957T2 (de) 1999-07-01
ES2127819T3 (es) 1999-05-01
JP2669721B2 (ja) 1997-10-29
HU224917B1 (en) 2006-04-28
AU4033993A (en) 1993-11-29
WO1993021894A2 (en) 1993-11-11
CA2133998C (en) 2006-03-21
NO944018L (no) 1994-10-21
HUT72295A (en) 1996-04-29
BR9306283A (pt) 1998-06-30
HU9403052D0 (en) 1994-12-28
WO1993021894A3 (en) 1994-01-20
US5242950A (en) 1993-09-07
CA2133998A1 (en) 1993-11-11
JPH07505906A (ja) 1995-06-29
NO944018D0 (no) 1994-10-21

Similar Documents

Publication Publication Date Title
DK0637238T3 (da) Behandling af makuløs degenerering
ATE207355T1 (de) Behandlung von hyperproliferativen gefässerkrankungen
PT668763E (pt) Utilizacao de fenserina para a preparacao de medicamentos para tratar doencas do conhecimento
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
DK241287A (da) Anvendelse af glutamin til fremstilling af et laegemiddel til behandling af kataboliske forstyrrelser
MY104521A (en) Treatment of depression.
DE69206607D1 (de) Behandlung von kognitiven störungen.
DE69307702T2 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
DK675489D0 (da) Anvendelse af tpa-varianter til fremstilling af et terapeutisk praeparat til behandling af vaskulaere sygdomme
ES2117008T3 (es) Metodo de tratamiento con amperozida de la esquizofrenia resistente a la terapia.
EA200200559A1 (ru) Способ лечения и профилактики нейродегенеративных состояний
DE69800906T2 (de) Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
ATE316373T1 (de) Conagenin zur behandlung von ulzerativer kolitis und/oder morbus crohn
MX9704887A (es) Composiciones farmaceuticas para el tratamiento de trastornos depresivos.
DK8893D0 (da) Medicament for treatment or prevention of disease